Gastrointestinal stromal tumour GIST
Document Sample


Gastrointestinal stromal tumour
PBS authority application
Important information Patients who fail to achieve a response to 400 mg per
day, after a minimum of three months treatment, may
You must lodge this form for an adult patient starting have their dose increased to 600 mg per day. Authority
initial Pharmaceutical Benefit Scheme (PBS) applications for doses higher than 600 mg per day will
subsidised treatment with imatinib for metastatic or not be approved.
unresectable malignant gastrointestinal stromal tumour.
All applications for continuing treatment may be made
All applications must be in writing and must include by telephone to 1800 700 270* and select option 3 (8
sufficient information to determine the patient’s eligibility am and 5 pm EST Monday to Friday).
according to the PBS criteria.
For all initial applications supply: Assistance
• a copy of the pathology report supporting diagnosis If you need assistance in completing this form, call
of a gastrointestinal stromal tumour and confirming Medicare Australia on 1800 700 270* and select
option 3 (8 am to 5 pm EST Monday to Friday), or visit
the presence of CD117 on immunohistochemical
www.medicareaustralia.gov.au
staining
• a copy of the most recent (within two months of
Lodgement
application), computer tomography (CT) scan,
magnetic resonance imaging (MRI) or ultrasound Send the completed authority application form, all
assessment of the tumour(s) including whether or relevant attachments and a completed authority
not there is evidence of metastatic disease prescription form to:
Medicare Australia
• written evidence to support an application which is
Prior written approval of specialised drugs
being made on the basis of an unresectable tumour. Reply Paid 9826
All patients must start treatment at a dose of imatinib GPO Box 9826
not exceeding 400 mg per day for three months. Hobart TAS 7001
Authority prescriptions for a higher dose will not be (no stamp required if posted in Australia)
approved during this initial treatment period.
The information on this form is correct at the time of Tick where applicable ✓
publishing and is subject to change.
* Call charges apply from mobile or pay phones only
Authority prescription form
A completed authority prescription form must be
included with this document.
The medical indication section of the authority
prescription form does not need to be completed when
submitted with this supporting information form.
Applications for continuing treatment
Patients who achieve a response to treatment at an
imatinib dose of 400 mg per day should be continued
at this dose and assessed for response at regular
intervals.
A response to treatment is defined as a decrease from
baseline in the sum of the products of the perpendicular
diameters of all measurable lesions of 50% or greater.
(Response definition based on the Southwest Oncology
Group standard criteria, see Demetri et al. N Engl J Med
2002; 347: 472-80.)
Page 1 of 2 4107.28.10.08
Gastrointestinal stromal tumour
PBS authority application
Supporting information
For initial PBS subsidised treatment of adult patients Treatment date range
with imatinib for metastatic or unresectable malignant / / / /
gastrointestinal stromal tumour. from to
and
Complete all parts of the application has, within two months of the date of this application,
Print neatly in BLOCK LETTERS had assessment of the tumour(s) by either:
a computer tomography (CT scan)
Patient’s details or
1 Medicare/DVA card number a magnetic resonance imaging (MRI) scan
or
Reference number
an ultrasound assessment
2 Dr Mr Mrs Miss Ms Other
Attach all relevant reports and a completed
Family name authority prescription form.
First given name Prescriber’s details
5 Prescriber number
3 Date of birth
/ / 6 Family name
Conditions, criteria and prior treatment
First given name
4 To qualify for PBS authority approval, under this
criterion, the following conditions must be met.
The patient: 7 Work phone number
has metastatic malignant gastrointestinal ( )
stromal tumour(s)
or Alternative phone number
an unresectable malignant gastrointestinal stromal
tumour (written evidence must be supplied) Fax number
and ( )
has a pathology report which confirms the presence
of CD117 on immunohistochemical staining Prescriber’s declaration
Give the following details from the report
8 I declare that the information provided on this form is
Approved pathology authority (APA) name true and correct.
Prescriber’s signature
Date of report Date
/ / - / /
and
Privacy note
has not received any prior treatment with
imatinib for GIST The information provided on this form will be used to
or assess applications and eligibility for the nominated patient
is currently receiving unsubsidised treatment under the restrictions for PBS subsidised treatment for
with imatinib for GIST gastrointestinal stromal tumour. The collection of this
Provide details of dose and duration of treatment information is authorised by the National Health Act 1953
and may be disclosed to the Department of Health and
Dose mg/day Ageing, or as authorised or required by law.
Page 2 of 2 4107.28.10.08
Get documents about "